Study to Evaluate the Efficacy and Safety of BMN 333 Versus Vosoritide in Children With Achondroplasia
for Achondroplasia
8 locations incl. Oakland
Sponsor: BioMarin Pharmaceutical
Sex: All·Age: 2 - 17
Code: NCT07441876·Phase 2, Phase 3·Recruiting·Listed Mar 2026